Yahoo
NYSE - Nasdaq Real Time Price USD

Veeva Systems Inc. (VEEV)

311.64 +1.30 (+0.42%)
As of 3:40:44 PM EDT. Market Open.
Trade VEEV on Coinbase
Chart Range Bar
Loading chart for VEEV

What's happening with VEEV?

14m ago
Powered by Yahoo Scout

Veeva Systems enters its fiscal third-quarter 2027 report with raised full-year guidance, strong prior-quarter execution, and growing interest in AI-powered customer relationship management (CRM) tools. The central debate is whether Vault CRM, Falcon, and other AI products can accelerate subscription growth enough to support the company’s premium valuation.

Powered by Yahoo Scout
  • Previous Close 310.34
  • Open 312.06
  • Bid 310.99 x 70000
  • Ask 311.39 x 10000
  • Day's Range 309.42 - 314.50
  • 52 Week Range 148.05 - 325.99
  • Volume 853,938
  • Avg. Volume 1,701,554
  • Market Cap (intraday) 50.457B
  • Beta (5Y Monthly) 0.93
  • PE Ratio (TTM) 51.09
  • EPS (TTM) 6.10
  • Earnings Date (est.) Nov 25, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 301.11
  • Morningstar Rating Rating available with Stock Picks access

Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. The company offers Veeva Commercial Cloud comprising Veeva Vault CRM Suite for pharmaceutical and biotechnology companies; Veeva Medical that provides source of medical content across multiple channels and geographies; Veeva PromoMats, an end-to-end content and digital asset management solution; and Veeva Crossix, an analytics platform for pharmaceutical brands. It also provides Veeva Data Cloud, such as Veeva OpenData, a customer reference data solution; Veeva Link, which provides deep data; Veeva Compass, which includes de-identified and longitudinal patient data; and Veeva CRM Pulse that provides access and multichannel engagement metrics. In addition, the company offers Veeva Development Cloud consisting of Veeva Clinical Platform, which advances clinical trial execution; Veeva Clinical Data Management that helps sponsors and CROs design and run trials; Veeva Safety, which unifies systems and processes; Veeva RIM that provides regulatory information management capabilities, as well as Veeva Quality Cloud, which is used by the life sciences and consumer products industries; and Veeva Business Consulting services. Further, it provides professional and support services, including implementation and deployment planning, and project management; requirements analysis, solution design, and configuration; systems environment management and deployment; services focused on advancing or transforming business and operating processes; technical consulting services on data migration and systems integrations; training; and ongoing managed services, such as outsourced systems administration. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.

www.veeva.com

7,928

Full Time Employees

January 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

VEEV
39.60%
S&P 500 (^GSPC)
10.45%

1-Year Return

VEEV
9.34%
S&P 500 (^GSPC)
10.82%

3-Year Return

VEEV
63.78%
S&P 500 (^GSPC)
81.45%

5-Year Return

VEEV
1.69%
S&P 500 (^GSPC)
64.17%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY27
Revenue 927.96M
Earnings 273.43M
Profit Margin 29.47%

Q3

FY26

Q4

FY26

Q1

FY27

Q2

FY27

0
200M
400M
600M
800M
29.2%
29.3%
29.4%
29.5%

Analyst Insights

View More

Analyst Price Targets

180.00 Low
301.11 Average
311.64 Current
375.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/28/2026
Analyst Barclays
Rating Action Maintains
Rating Overweight
Price Action Raises
Price Target 360 -> 375

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    29.34%

  • Return on Assets (ttm)

    7.58%

  • Return on Equity (ttm)

    14.43%

  • Revenue (ttm)

    3.46B

  • Net Income Avi to Common (ttm)

    1.01B

  • Diluted EPS (ttm)

    6.10

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.24B

  • Total Debt/Equity (mrq)

    2.04%

  • Levered Free Cash Flow (ttm)

    1.26B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: